Biogen Shortens Its Name, Expands Focus On Alzheimer’s Treatments

Biogen Shortens Its Name, Expands Focus On Alzheimer’s Treatments
biogen nlThanks to its successful drugs to address treatments for multiple sclerosis, Biogen Idec Inc has seen its position in the biopharmaceutical market increase, having quadrupled sales in just 3 years to over $100 billion dollars. The company now has new ambitions in sight and has dropped "Idec" from its name and adopted a new logo to indicate its new focus, which will include drug development efforts for Alzheimer's disease. The Massachusetts-based
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *